Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders--a clinicopathological study on 575 patients.
Contrasting the circulating CD34+ hematopoietic progenitor cells (HPCs) in chronic myeloproliferative disorders (CMPDs), scant knowledge is available regarding their quantity in the bone marrow (BM). Therefore, a clinicopathological study was performed on trephine biopsies in 575 patients with CMPDs focused on chronic idiopathic myelofibrosis (CIMF). A comparison with 25 healthy subjects revealed no significant differences in the numbers of HPCs (6 +/- 3/mm2) in polycythemia vera, essential thrombocythemia and advanced fibro-osteosclerotic stages of CIMF. Pre-fibrotic and early-stage CIMF displayed 16 +/- 11 precursors per mm2 BM. Sequential biopsies in this disorder showed a decline in HPCs (10 +/- 6/mm2) with evolving myelofibrosis-myeloid metaplasia (MMM), while in terminal stages acceleration generated an increase (24 +/- 25/mm2). A significant association between the quantity of HPCs and the development of myelofibrosis, splenomegaly, and anemia as well as an increase in peripheral blasts was recognizable in CIMF. Moreover, in all subtypes of CMPDs, a favorable prognosis was significantly associated with a higher number of HPCs in the BM. In conclusion, enhanced inflow of precursors from the BM with subsequent trapping, self-renewal and mobilization by the spleen is assumed to indicate a progressive generalization and worsening of the outcome. This putative pathomechanism is significantly associated with the evolution of MMM.
Thiele
Juergen
J
Institute of Pathology, University of Cologne, Cologne, Germany. j.thiele@uni-koeln.de
Kvasnicka
Hans Michael
HM
Diehl
Volker
V
D018952:Antigens, CD34 / Q000378:metabolism*; D001706:Biopsy; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology*; D002908:Chronic Disease; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000276:immunology / Q000473:pathology*; D009196:Myeloproliferative Disorders / Q000276:immunology / Q000473:pathology*; D055728:Primary Myelofibrosis / Q000276:immunology / Q000473:pathology; D012189:Retrospective Studies
D018952:Antigens, CD34